Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review

Area of Science:

• Hepatology
• Virology
• Clinical Trials

Background:

• Several randomized trials investigated shorter treatment durations (12-16 weeks) for Hepatitis C virus (HCV) genotypes 2 and 3 using PEG IFNs and ribavirin.
• Previous phase 3 trials established a standard treatment duration of 24 weeks.

Purpose of the Study:

• To evaluate if reducing therapy duration to 12-16 weeks is non-inferior to standard 24-week treatment for HCV genotypes 2 and 3.
• To identify predictors of sustained virologic response (SVR) to guide treatment decisions.

Main Methods:

• Analysis of large-scale randomized trials (ACCELERATE, NORTH-C, NORDynamIC) comparing short-duration versus standard-duration therapy.
• Intention-to-treat analysis was used to assess treatment efficacy.
• Evaluation of rapid virological response (RVR) as a predictor of SVR.

Main Results:

• The largest studies failed to demonstrate non-inferiority of short treatment (12-16 weeks) compared to standard 24-week therapy.
• Despite trial variations, all studies confirmed rapid virological response (HCV-RNA negative at 4 weeks) as the strongest predictor of SVR.
• Identifying baseline risk factors and early treatment response features can enable response-guided treatment duration reduction.

Conclusions:

• Current evidence does not support reducing standard therapy duration for HCV genotypes 2 and 3 to 12-16 weeks based on non-inferiority trials.
• Response-guided therapy, utilizing RVR and baseline risk factors, is a viable strategy for optimizing treatment duration in HCV-2 and HCV-3 patients.
• Further research is ongoing to determine if extended 48-week regimens benefit non-RVR patients, particularly those with advanced fibrosis.